Latin America turned to Russia when the West ran short
En los últimos días de 2020, Bolivia se unió a una corriente regional que buscaba respuestas más allá de las fronteras occidentales: el gobierno firmó un acuerdo con Rusia para adquirir 5,2 millones de dosis de la vacuna Sputnik V, convirtiéndose en el tercer país latinoamericano —tras Argentina y Venezuela— en recurrir a Moscú en medio de la urgencia pandémica. En un mundo donde el acceso a las vacunas reflejaba ya las geometrías del poder global, esta decisión habla de la búsqueda de soberanía sanitaria por parte de naciones que no podían esperar.
- Bolivia enfrentaba una presión creciente para proteger a su población mientras las naciones más ricas acaparaban las vacunas de los laboratorios occidentales.
- La firma del contrato en la Casa Grande del Pueblo marcó un punto de inflexión: el país elegía un camino propio en lugar de aguardar en una fila global que no le favorecía.
- Argentina ya aplicaba sus primeras dosis esa misma semana y Venezuela anunciaba su acuerdo el mismo día, revelando una coordinación tácita entre gobiernos latinoamericanos afines.
- La Sputnik V, con una eficacia reportada del 91,4% en ensayos de fase 3 y una plataforma de doble vector adenoviral sin virus vivos replicantes, ofrecía argumentos científicos concretos para justificar la elección.
- Con más de cinco millones de dosis aseguradas, Bolivia apostaba por una ruta viable aunque todavía debatida en otras partes del mundo, señalando que la diversificación de proveedores se volvía estrategia, no excepción.
A finales de diciembre de 2020, el gobierno boliviano formalizó un contrato con Rusia para adquirir 5,2 millones de dosis de la vacuna Sputnik V contra el coronavirus. El acuerdo se selló en la Casa Grande del Pueblo, en La Paz, y convirtió a Bolivia en el tercer país sudamericano en llegar a ese tipo de entendimiento con Moscú.
El contexto regional era elocuente: Argentina había comenzado a vacunar esa misma semana, y Venezuela anunció su propio acuerdo el mismo martes en que Bolivia hacía pública su decisión. Mientras las naciones más ricas del hemisferio norte aseguraban suministros con los grandes laboratorios occidentales, los gobiernos latinoamericanos encontraban en el proveedor ruso una alternativa concreta ante la escasez.
La Sputnik V se basa en una plataforma de doble vector adenoviral —Ad26 y Ad5— que requiere dos inyecciones. Los vectores utilizados son modificados e incapaces de replicarse, lo que sus desarrolladores presentaron como una garantía de seguridad. La tecnología no era nueva: se apoyaba en una plataforma con antecedentes en otras vacunas. Los ensayos clínicos de fase 3 reportaron una eficacia del 91,4%, cifra que se volvió central en los debates sobre su confiabilidad.
Para Bolivia, comprometerse con más de cinco millones de dosis representó una apuesta significativa: la convicción de que la vacuna rusa ofrecía un camino real hacia la protección de su población, en un momento en que las alternativas escaseaban y el tiempo apremiaba.
Bolivia's government signed a contract with Russia in late December 2020 to acquire 5.2 million doses of the Sputnik V coronavirus vaccine, marking a significant moment in the country's pandemic response. The agreement was formalized at the Casa Grande del Pueblo, the presidential palace in La Paz, positioning Bolivia as the third nation in South America to strike such a deal with Moscow.
Argentina had moved first, having already begun administering its initial doses that same week. Venezuela followed shortly after, announcing its own purchase agreement on the same Tuesday that Bolivia's deal became public. The sequence reflected a broader regional shift: as wealthy nations in North America and Europe secured supplies from Western pharmaceutical manufacturers, Latin American governments were turning to Russian suppliers to fill the gap.
Sputnik V operates on a two-vector adenovirus platform, using distinct viral vectors labeled Ad26 and Ad5. The vaccine requires two injections spaced apart. The technology does not employ live human adenoviruses; instead, it uses modified adenoviral vectors incapable of replicating, a distinction the developers emphasized as a safety feature. This dual-vector approach was not new—it built on an established platform that had been used to create other vaccines in the past.
According to data from Phase 3 clinical trials, Sputnik V demonstrated an efficacy rate of 91.4 percent. This figure would become central to discussions about the vaccine's reliability as countries weighed their procurement options during the urgent early months of the global vaccination campaign.
Bolivia's decision to secure over five million doses represented a substantial commitment to vaccinating its population. The agreement came at a moment when the country, like much of Latin America, faced mounting pressure to protect its citizens while navigating supply constraints and competing international interests. The move signaled that Bolivian officials believed the Russian vaccine represented a viable path forward, even as debates about its approval and efficacy continued in other parts of the world.
Citações Notáveis
Sputnik V uses modified adenoviral vectors incapable of replicating, described as completely safe for health— vaccine developers
A Conversa do Hearth Outra perspectiva sobre a história
Why did Bolivia move so quickly to sign with Russia when other options existed?
At that moment in late 2020, options were scarce. Western manufacturers had already committed their early supplies to wealthier nations. Bolivia needed doses, and Russia was offering them. Argentina had already started vaccinating with Sputnik, which provided a kind of proof of concept.
Did the government face domestic criticism for choosing a Russian vaccine?
The source doesn't capture that debate, but it's worth noting that geopolitics and vaccine choice were inseparable. Some countries viewed Sputnik with suspicion; others saw it as pragmatism. Bolivia was simply trying to protect its people.
The efficacy number—91.4 percent—how did that compare to what was available elsewhere?
It was competitive. Pfizer and Moderna were reporting similar or slightly higher numbers at that time. The real difference was availability, not performance. Bolivia couldn't wait for Western supplies that might never arrive.
What does this tell us about power and access in a pandemic?
Everything. The countries that could afford to be choosy were wealthy. Everyone else took what they could get. Bolivia's agreement with Russia wasn't ideological—it was survival.